<?xml version="1.0" encoding="UTF-8"?>

<ResearchStudy xmlns="http://hl7.org/fhir">
  <id value="ECLAIREResearchStudy-example-2022-500014-26-00"/>
  <meta>
    <lastUpdated value="2023-04-12T00:00:00.000Z"/>
    <profile value="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"/>
  </meta>
  <text>
    <status value="extensions"/><div xmlns="http://www.w3.org/1999/xhtml"><p><b>Generated Narrative: ResearchStudy</b><a name="ECLAIREResearchStudy-example-2022-500014-26-00"> </a></p><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Resource ResearchStudy &quot;ECLAIREResearchStudy-example-2022-500014-26-00&quot; Updated &quot;2023-04-12 00:00:00+0000&quot; </p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-eclaire-researchstudy.html">ECLAIREResearchStudy</a></p></div><p><b>ECLAIRESecondarySponsor</b>: <a href="Organization/2022-500014-26-00-secondary-sponsor">Organization/2022-500014-26-00-secondary-sponsor: Reference to secondary sponsor</a></p><p><b>ECLAIRETherapeuticArea</b>: Diseases [C] - Neoplasms [C04]</p><blockquote><p><b>ECLAIRELabelR5</b></p><blockquote><p><b>url</b></p><code>value</code></blockquote><p><b>value</b>: INDISPONIBLE</p><blockquote><p><b>url</b></p><code>type</code></blockquote><p><b>value</b>: Label Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-eclaire-study-title-type-code-system.html">Définition des types de titre pour l'essai[0.2.0]</a>#human-use &quot;Human use&quot;)</span></p></blockquote><blockquote><p><b>ECLAIRELabelR5</b></p><blockquote><p><b>url</b></p><code>value</code></blockquote><p><b>value</b>: INDISPONIBLE</p><blockquote><p><b>url</b></p><code>type</code></blockquote><p><b>value</b>: Label Type <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-eclaire-study-title-type-code-system.html">Définition des types de titre pour l'essai[0.2.0]</a>#acronym &quot;Acronym&quot;)</span></p></blockquote><p><b>ECLAIRERecruitmentPeriod</b>: 2022-06-30 00:00:00+0000 --&gt; (ongoing)</p><p><b>ECLAIREReviewDate</b>: Apr 12, 2023, 12:00:00 AM</p><p><b>identifier</b>: id: INDISPONIBLE (use: OFFICIAL), id: 2022-500014-26-00 (use: SECONDARY)</p><p><b>title</b>: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER</p><p><b>status</b>: active</p><p><b>phase</b>: Research Study Phase <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ResearchStudyPhase[4.0.1]#phase-3 &quot;Phase 3&quot;)</span></p><p><b>category</b>: Regulation Code <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-eclaire-regulation-code-code-system.html">Code de régulation de l'essai[0.2.0]</a>#REG536 &quot;REG536 (CTIS)&quot;)</span>, Reglementation Precision <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (<a href="CodeSystem-eclaire-reglementation-precision-code-system.html">Précision sur la réglementation concernant l'essai[0.2.0]</a>#study-ctis &quot;un essai clinique (CTIS)&quot;)</span></p><p><b>condition</b>: diseaseCondition <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> ([not stated] &quot;Locally-Advanced or Metastatic breast cancer (MBC)&quot;)</span>, medDRACondition <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (mdr[2.0.1]#10070575 &quot;Cancer du sein à récepteurs aux oestrogènes positifs&quot;)</span>, medDRACondition <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (mdr[2.0.1]#10065430 &quot;Cancer du sein HER2 positif&quot;)</span></p><p><b>contact</b>: ph: 0041616881111(WORK),<a href="mailto:global.rochegenentechtrials@roche.com">global.rochegenentechtrials@roche.com</a>, ph: INDISPONIBLE(WORK),<a href="mailto:INDISPONIBLE">INDISPONIBLE</a>, ph: INDISPONIBLE(WORK),<a href="mailto:INDISPONIBLE">INDISPONIBLE</a></p><p><b>location</b>: Countries of recruitment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#BE &quot;Belgium&quot;)</span>, Countries of recruitment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#DE &quot;Germany&quot;)</span>, Countries of recruitment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#ES &quot;Spain&quot;)</span>, Countries of recruitment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#FR &quot;France&quot;)</span>, Countries of recruitment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#HU &quot;Hungary&quot;)</span>, Countries of recruitment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#IT &quot;Italy&quot;)</span>, Countries of recruitment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#PL &quot;Poland&quot;)</span>, Countries of recruitment <span style="background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki"> (ISO 3166-1 Codes for the representation of names of countries and their subdivisions — Part 1: Country code[4.0.1]#PT &quot;Portugal&quot;)</span></p><p><b>description</b>: INDISPONIBLE</p><p><b>enrollment</b>: <a href="Group/2022-500014-26-00-enrollment-group">Group/2022-500014-26-00-enrollment-group: Reference to group detailing study characteristics</a></p><p><b>sponsor</b>: <a href="Organization/2022-500014-26-00-primary-sponsor">Organization/2022-500014-26-00-primary-sponsor: Reference to primary sponsor</a></p></div>
  </text>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-secondary-sponsor">
    <valueReference>
      <reference value="Organization/2022-500014-26-00-secondary-sponsor"/>
      <type value="Organization"/>
      <display value="Reference to secondary sponsor"/>
    </valueReference>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area">
    <valueString value="Diseases [C] - Neoplasms [C04]"/>
  </extension>
  <extension url="http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.label">
    <extension url="value">
      <valueString value="INDISPONIBLE"/>
    </extension>
    <extension url="type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-title-type-code-system"/>
          <version value="0.2.0"/>
          <code value="human-use"/>
          <display value="Human use"/>
        </coding>
        <text value="Label Type"/>
      </valueCodeableConcept>
    </extension>
  </extension>
  <extension url="http://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.label">
    <extension url="value">
      <valueString value="INDISPONIBLE"/>
    </extension>
    <extension url="type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-title-type-code-system"/>
          <version value="0.2.0"/>
          <code value="acronym"/>
          <display value="Acronym"/>
        </coding>
        <text value="Label Type"/>
      </valueCodeableConcept>
    </extension>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period">
    <valuePeriod>
      <start value="2022-06-30T00:00:00.000Z"/>
    </valuePeriod>
  </extension>
  <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-review-date">
    <valueInstant value="2023-04-12T00:00:00.000Z"/>
  </extension>
  <identifier>
    <use value="official"/>
    <value value="INDISPONIBLE"/>
    <assigner>
      <type value="Organization"/>
      <display value="Reference to primary assigner"/>
    </assigner>
  </identifier>
  <identifier>
    <use value="secondary"/>
    <value value="2022-500014-26-00"/>
    <assigner>
      <reference value="Organization/ctis"/>
      <type value="Organization"/>
      <display value="Reference to secondary assigner"/>
    </assigner>
  </identifier>
  <title value="A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER"/>
  <status value="active"/>
  <phase>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/research-study-phase"/>
      <version value="4.0.1"/>
      <code value="phase-3"/>
      <display value="Phase 3"/>
    </coding>
    <text value="Research Study Phase"/>
  </phase>
  <category>
    <coding>
      <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system"/>
      <version value="0.2.0"/>
      <code value="REG536"/>
      <display value="REG536 (CTIS)"/>
    </coding>
    <text value="Regulation Code"/>
  </category>
  <category>
    <coding>
      <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system"/>
      <version value="0.2.0"/>
      <code value="study-ctis"/>
      <display value="un essai clinique (CTIS)"/>
    </coding>
    <text value="Reglementation Precision"/>
  </category>
  <condition>
    <coding>
      <display value="Locally-Advanced or Metastatic breast cancer (MBC)"/>
    </coding>
    <text value="diseaseCondition"/>
  </condition>
  <condition>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/mdr"/>
      <version value="2.0.1"/>
      <code value="10070575"/>
      <display value="Cancer du sein à récepteurs aux oestrogènes positifs"/>
    </coding>
    <text value="medDRACondition"/>
  </condition>
  <condition>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/mdr"/>
      <version value="2.0.1"/>
      <code value="10065430"/>
      <display value="Cancer du sein HER2 positif"/>
    </coding>
    <text value="medDRACondition"/>
  </condition>
  <contact>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name">
      <valueHumanName>
        <use value="official"/>
        <family value="Trial Information Support Line-TISL, Switzerland"/>
        <given value="Head of EU"/>
      </valueHumanName>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address">
      <valueAddress>
        <use value="work"/>
        <type value="physical"/>
        <line value="INDISPONIBLE"/>
        <city value="INDISPONIBLE"/>
        <postalCode value="INDISPONIBLE"/>
        <country value="INDISPONIBLE"/>
      </valueAddress>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-affiliation">
      <valueString value="INDISPONIBLE"/>
    </extension>
    <telecom>
      <system value="phone"/>
      <value value="0041616881111"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="global.rochegenentechtrials@roche.com"/>
      <use value="work"/>
    </telecom>
  </contact>
  <contact>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name">
      <valueHumanName>
        <use value="official"/>
        <family value="INDISPONIBLE"/>
        <given value="INDISPONIBLE"/>
      </valueHumanName>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address">
      <valueAddress>
        <use value="work"/>
        <type value="physical"/>
        <line value="INDISPONIBLE"/>
        <city value="INDISPONIBLE"/>
        <postalCode value="INDISPONIBLE"/>
        <country value="INDISPONIBLE"/>
      </valueAddress>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-affiliation">
      <valueString value="INDISPONIBLE"/>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system"/>
          <version value="0.1.0"/>
          <code value="SCI"/>
          <display value="Scientifique / Scientific"/>
        </coding>
        <text value="Contact Type"/>
      </valueCodeableConcept>
    </extension>
    <telecom>
      <system value="phone"/>
      <value value="INDISPONIBLE"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="INDISPONIBLE"/>
      <use value="work"/>
    </telecom>
  </contact>
  <contact>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name">
      <valueHumanName>
        <use value="official"/>
        <family value="INDISPONIBLE"/>
        <given value="INDISPONIBLE"/>
      </valueHumanName>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address">
      <valueAddress>
        <use value="work"/>
        <type value="physical"/>
        <line value="INDISPONIBLE"/>
        <city value="INDISPONIBLE"/>
        <postalCode value="INDISPONIBLE"/>
        <country value="INDISPONIBLE"/>
      </valueAddress>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-affiliation">
      <valueString value="INDISPONIBLE"/>
    </extension>
    <extension url="https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type">
      <valueCodeableConcept>
        <coding>
          <system value="https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system"/>
          <version value="0.1.0"/>
          <code value="PUB"/>
          <display value="Publique / Public"/>
        </coding>
        <text value="Contact Type"/>
      </valueCodeableConcept>
    </extension>
    <telecom>
      <system value="phone"/>
      <value value="INDISPONIBLE"/>
      <use value="work"/>
    </telecom>
    <telecom>
      <system value="email"/>
      <value value="INDISPONIBLE"/>
      <use value="work"/>
    </telecom>
  </contact>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="BE"/>
      <display value="Belgium"/>
    </coding>
    <text value="Countries of recruitment"/>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="DE"/>
      <display value="Germany"/>
    </coding>
    <text value="Countries of recruitment"/>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="ES"/>
      <display value="Spain"/>
    </coding>
    <text value="Countries of recruitment"/>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="FR"/>
      <display value="France"/>
    </coding>
    <text value="Countries of recruitment"/>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="HU"/>
      <display value="Hungary"/>
    </coding>
    <text value="Countries of recruitment"/>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="IT"/>
      <display value="Italy"/>
    </coding>
    <text value="Countries of recruitment"/>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="PL"/>
      <display value="Poland"/>
    </coding>
    <text value="Countries of recruitment"/>
  </location>
  <location>
    <coding>
      <system value="urn:iso:std:iso:3166"/>
      <version value="4.0.1"/>
      <code value="PT"/>
      <display value="Portugal"/>
    </coding>
    <text value="Countries of recruitment"/>
  </location>
  <description value="INDISPONIBLE"/>
  <enrollment>
    <reference value="Group/2022-500014-26-00-enrollment-group"/>
    <type value="Group"/>
    <display value="Reference to group detailing study characteristics"/>
  </enrollment>
  <sponsor>
    <reference value="Organization/2022-500014-26-00-primary-sponsor"/>
    <type value="Organization"/>
    <display value="Reference to primary sponsor"/>
  </sponsor>
</ResearchStudy>